Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharmaceuticals International is to initiate development of its hepatitis C drug in Japan, following the first meeting of the company's hepatitis C Japanese advisory board, held in Tokyo.
Subscribe to our email newsletter
The company is developing Viramidine in oral form for administration in combination with pegylated interferon for the treatment of chronic hepatitis C. Valeant is currently conducting two pivotal phase III trials for Viramidine in major markets around the world.
“Japan represents the world’s second largest hepatitis C market, with an estimated 2.3 million people infected,” Valeant’s president and CEO, Timothy Tyson, said.
“Our hope is that Viramidine’s potentially improved safety profile could be of great benefit to hepatitis C patients in Japan, especially when you consider that many physicians believe that Japanese patients tend to be more prone to developing anemia. We remain confident in Viramidine’s potential and look forward to presenting the results of the first of two global phase III trials in the first half of 2006.”